<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE rdf:RDF [
	<!ENTITY cmns-av "https://www.omg.org/spec/Commons/AnnotationVocabulary/">
	<!ENTITY cmns-cmp "https://www.omg.org/spec/Commons/Composites/">
	<!ENTITY cmns-col "https://www.omg.org/spec/Commons/Collections/">
	<!ENTITY cmns-cxtdsg "https://www.omg.org/spec/Commons/ContextualDesignators/">
	<!ENTITY cmns-ge-euj "https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/">
	<!ENTITY cmns-id "https://www.omg.org/spec/Commons/Identifiers/">
	<!ENTITY cmns-org "https://www.omg.org/spec/Commons/Organizations/">
	<!ENTITY cmns-ra "https://www.omg.org/spec/Commons/RegistrationAuthorities/">
	<!ENTITY cmns-txt "https://www.omg.org/spec/Commons/TextDatatype/">
	<!ENTITY dct "http://purl.org/dc/terms/">
	<!ENTITY idmp-amp "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/AmlodipineExample/">
	<!ENTITY idmp-chg "https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/">
	<!ENTITY idmp-euctr "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/EuropeanUnionClinicalTrialsRegister/">
	<!ENTITY idmp-eura "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/">
	<!ENTITY idmp-eurga "https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/">
	<!ENTITY idmp-mprd "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/">
	<!ENTITY idmp-ra "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/">
	<!ENTITY idmp-sub "https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/">
	<!ENTITY idmp-trlp "https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/TerlipressinExample/">
	<!ENTITY lcc-3166-1 "https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/">
	<!ENTITY lcc-cr "https://www.omg.org/spec/LCC/Countries/CountryRepresentation/">
	<!ENTITY owl "http://www.w3.org/2002/07/owl#">
	<!ENTITY rdf "http://www.w3.org/1999/02/22-rdf-syntax-ns#">
	<!ENTITY rdfs "http://www.w3.org/2000/01/rdf-schema#">
	<!ENTITY skos "http://www.w3.org/2004/02/skos/core#">
	<!ENTITY xsd "http://www.w3.org/2001/XMLSchema#">
]>
<rdf:RDF xml:base="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/EuropeanUnionClinicalTrialsRegister/"
	xmlns:cmns-av="https://www.omg.org/spec/Commons/AnnotationVocabulary/"
	xmlns:cmns-cmp="https://www.omg.org/spec/Commons/Composites/"
	xmlns:cmns-col="https://www.omg.org/spec/Commons/Collections/"
	xmlns:cmns-cxtdsg="https://www.omg.org/spec/Commons/ContextualDesignators/"
	xmlns:cmns-ge-euj="https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/"
	xmlns:cmns-id="https://www.omg.org/spec/Commons/Identifiers/"
	xmlns:cmns-org="https://www.omg.org/spec/Commons/Organizations/"
	xmlns:cmns-ra="https://www.omg.org/spec/Commons/RegistrationAuthorities/"
	xmlns:cmns-txt="https://www.omg.org/spec/Commons/TextDatatype/"
	xmlns:dct="http://purl.org/dc/terms/"
	xmlns:idmp-amp="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/AmlodipineExample/"
	xmlns:idmp-chg="https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/"
	xmlns:idmp-euctr="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/EuropeanUnionClinicalTrialsRegister/"
	xmlns:idmp-eura="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/"
	xmlns:idmp-eurga="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/"
	xmlns:idmp-mprd="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/"
	xmlns:idmp-ra="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/"
	xmlns:idmp-sub="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/"
	xmlns:idmp-trlp="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/TerlipressinExample/"
	xmlns:lcc-3166-1="https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/"
	xmlns:lcc-cr="https://www.omg.org/spec/LCC/Countries/CountryRepresentation/"
	xmlns:owl="http://www.w3.org/2002/07/owl#"
	xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
	xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
	xmlns:skos="http://www.w3.org/2004/02/skos/core#"
	xmlns:xsd="http://www.w3.org/2001/XMLSchema#">
	
	<owl:Ontology rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/EuropeanUnionClinicalTrialsRegister/">
		<rdfs:label>European Union Clincal Trials Register Ontology</rdfs:label>
		<dct:abstract>The ontology provides an instance-based seed example for some of the data related to clincal trials representation.</dct:abstract>
		<dct:license rdf:datatype="&xsd;anyURI">https://opensource.org/licenses/MIT</dct:license>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/AmlodipineExample/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/TerlipressinExample/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/EuropeanJurisdiction/EuropeanRegulatoryAgencies/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-RegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11238-Substances/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/ISO/ISO11615-MedicinalProducts/"/>
		<owl:imports rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/META/ChangeManagement/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/AnnotationVocabulary/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Collections/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Composites/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/ContextualDesignators/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/EuropeanJurisdiction/EUGovernmentEntitiesAndJurisdictions/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Identifiers/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/Organizations/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/RegistrationAuthorities/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/Commons/TextDatatype/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Countries/CountryRepresentation/"/>
		<owl:imports rdf:resource="https://www.omg.org/spec/LCC/Countries/ISO3166-1-CountryCodes/"/>
		<owl:versionIRI rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/20230901/Examples/EuropeanUnionClinicalTrialsRegister/"/>
		<idmp-chg:hasMaturityLevel rdf:resource="&idmp-chg;Informative"/>
		<cmns-av:copyright>Copyright (c) 2022-2023 EDM Council, Inc.</cmns-av:copyright>
		<cmns-av:copyright>Copyright (c) 2022-2023 Pistoia Alliance, Inc.</cmns-av:copyright>
		<cmns-av:usageNote>This example is for illustration purposes only. The data provided may not be up-to-date, and in some cases, &apos;dummy&apos; data has been included. The product information included here shall not be used for any other purpose than for educational purposes regarding the IDMP-O implementation.</cmns-av:usageNote>
	</owl:Ontology>
	
	<owl:NamedIndividual rdf:about="https://gsrs.ncats.nih.gov/api/v1/substances/bba69d15-f55c-4f0d-8e24-e61b60f2a115">
		<rdf:type rdf:resource="&idmp-sub;ChemicalSubstance"/>
		<rdfs:label>aluminum hydroxide</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://gsrs.ncats.nih.gov/api/v1/substances/beaecfe8-eccb-44ab-b842-ae2cc60ff3e4">
		<rdf:type rdf:resource="&idmp-sub;ChemicalSubstance"/>
		<rdfs:label>aluminum phosphate</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://gsrs.ncats.nih.gov/api/v1/substances/c9925b82-5d36-4e00-b54d-d3b7189625de">
		<rdf:type rdf:resource="&idmp-sub;ChemicalSubstance"/>
		<rdfs:label>1-3-O-desacyl-4&apos; monophosphoryl lipid A</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://gsrs.ncats.nih.gov/api/v1/substances/e67c9314-1e17-4876-a745-47f27c2169e6">
		<rdf:type rdf:resource="&idmp-sub;Mixture"/>
		<rdfs:label>hepatitis B surface antigen</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;Aliskiren">
		<rdf:type rdf:resource="&idmp-mprd;PharmaceuticalProduct"/>
		<rdfs:label>aliskiren</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;AliskirenAsInvestigationalMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;InvestigationalMedicinalProduct"/>
		<rdfs:label>aliskiren as investigational medicinal product</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-euctr;AliskirenMedicinalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;AliskirenMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>aliskiren medicinal product</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;Aliskiren"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;AluminumHydroxideAsActiveIngredient">
		<rdf:type rdf:resource="&idmp-sub;ActiveIngredient"/>
		<rdfs:label>aluminum hydroxide as an active ingredient</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://gsrs.ncats.nih.gov/api/v1/substances/bba69d15-f55c-4f0d-8e24-e61b60f2a115"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;AluminumPhosphateAsActiveIngredient">
		<rdf:type rdf:resource="&idmp-sub;ActiveIngredient"/>
		<rdfs:label>Aluminum Phosphate as an active ingredient</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://gsrs.ncats.nih.gov/api/v1/substances/beaecfe8-eccb-44ab-b842-ae2cc60ff3e4"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;ClinicalTrialAuthorization-2004-002410-11">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrialAuthorization"/>
		<rdfs:label>clinical trial authorization 2004-002410-11</rdfs:label>
		<idmp-mprd:hasAuthorizedParty rdf:resource="&idmp-euctr;NovartisPharmaServicesAGAuthorizedParty"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-cxtdsg:appliesTo rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002410-11/DE"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&lcc-3166-1;Germany"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;ClinicalTrialAuthorization-2010-022372-31">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrialAuthorization"/>
		<rdfs:label>clinical trial authorization 2010-022372-31</rdfs:label>
		<idmp-mprd:hasAuthorizedParty rdf:resource="&idmp-euctr;DynavaxTechnologiesCorporationAsAuthorizedParty"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-cxtdsg:appliesTo rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022372-31/DE"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&lcc-3166-1;Germany"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;ClinicalTrialAuthorization-2012-000236-26">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrialAuthorization"/>
		<rdfs:label>clinical trial authorization 2012-000236-26</rdfs:label>
		<idmp-mprd:hasAuthorizedParty rdf:resource="&idmp-euctr;NovartisPharmaServicesAGAuthorizedParty"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-cxtdsg:appliesTo rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022372-31/DE"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&lcc-3166-1;UnitedKingdomOfGreatBritainAndNorthernIreland"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;ClinicalTrialAuthorization-2014-002112-16">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrialAuthorization"/>
		<rdfs:label>clinical trial authorization 2014-002112-16</rdfs:label>
		<idmp-mprd:hasAuthorizedParty rdf:resource="&idmp-euctr;SheffieldTeachingHospitalsNHSFoundationTrustAuthorizedParty"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-cxtdsg:appliesTo rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002112-16/GB"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&lcc-3166-1;UnitedKingdomOfGreatBritainAndNorthernIreland"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;DynavaxTechnologiesCorporation">
		<rdf:type rdf:resource="&cmns-org;LegalEntity"/>
		<rdfs:label>Dynavax Technologies Corporation</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;DynavaxTechnologiesCorporationAsAuthorizedParty">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedParty"/>
		<rdfs:label>Dynavax Technologies Corporation as authorized party</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-euctr;DynavaxTechnologiesCorporation"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;DynavaxTechnologiesCorporationAsMarketingAuthorizationHolder">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorizationHolder"/>
		<rdfs:label>Dynavax Technologies Corporation as marketing authorization holder</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-euctr;DynavaxTechnologiesCorporation"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EngerixBAsAuthorizedMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedMedicinalProduct"/>
		<rdfs:label>Engerix B as authorized medicinal product</rdfs:label>
		<idmp-mprd:hasAuthorization rdf:resource="&idmp-euctr;EngerixBMarketingAuthorizationInEuropeanUnion"/>
		<cmns-cmp:isPlayedBy rdf:resource="https://www.ema.europa.eu/en/medicines/human/referrals/engerix-b"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EngerixBAsInvestigationalMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;InvestigationalMedicinalProduct"/>
		<rdfs:label>Engerix B as investigational medicinal product</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://www.ema.europa.eu/en/medicines/human/referrals/engerix-b"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EngerixBMarketingAuthorizationInEuropeanUnion">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorization"/>
		<rdfs:label>Engerix B Market Authorization in European Union</rdfs:label>
		<idmp-mprd:hasAuthorizedParty rdf:resource="&idmp-euctr;GlaxoSmithKlineBiologicalsAsMarketingAuthorizationHolder"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-cxtdsg:appliesTo rdf:resource="&idmp-euctr;EngerixBAsAuthorizedMedicinalProduct"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&cmns-ge-euj;EuropeanUnionJurisdiction"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EngerixBPharmaceuticalProduct">
		<rdf:type rdf:resource="&idmp-mprd;PharmaceuticalProduct"/>
		<rdfs:label>Engerix B PP</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;AluminumHydroxideAsActiveIngredient"/>
		<cmns-col:comprises rdf:resource="&idmp-euctr;HepatitisBSurfaceAntigenAsActiveIngredient"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EudraClinicalTrialsNumber-2004-002410-11">
		<rdf:type rdf:resource="&idmp-eura;EudraClinicalTrialsNumber"/>
		<rdfs:label>Eudra clinical trials number 2004-002410-11</rdfs:label>
		<cmns-id:identifies rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002410-11/DE"/>
		<cmns-txt:hasTextValue>2004-002410-11</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EudraClinicalTrialsNumber-2010-022372-31">
		<rdf:type rdf:resource="&idmp-eura;EudraClinicalTrialsNumber"/>
		<rdfs:label>Eudra clinical trials number 2010-022372-31</rdfs:label>
		<cmns-id:identifies rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022372-31/DE"/>
		<cmns-txt:hasTextValue>2010-022372-31</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;EudraClinicalTrialsNumber-2014-002112-16">
		<rdf:type rdf:resource="&idmp-eura;EudraClinicalTrialsNumber"/>
		<rdfs:label>Eudra clinical trials number 2014-002112-16</rdfs:label>
		<cmns-id:identifies rdf:resource="https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002112-16/GB"/>
		<cmns-txt:hasTextValue>2014-002112-16</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;FendrixAsAuthorizedMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedMedicinalProduct"/>
		<rdfs:label>Fedrix as authorized medicinal product</rdfs:label>
		<idmp-mprd:hasAuthorization rdf:resource="&idmp-euctr;FendrixMarketingAuthorizationInEuropeanUnion"/>
		<cmns-cmp:isPlayedBy rdf:resource="https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;FendrixAsInvestigationalMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;InvestigationalMedicinalProduct"/>
		<rdfs:label>Fedrix as investigational medicinal product</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;FendrixMarketingAuthorizationInEuropeanUnion">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorization"/>
		<rdfs:label>Fedrix Market Authorization in European Union</rdfs:label>
		<idmp-mprd:hasAuthorizedParty rdf:resource="&idmp-euctr;GlaxoSmithKlineBiologicalsAsMarketingAuthorizationHolder"/>
		<idmp-mprd:hasAuthorizingParty rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-cxtdsg:appliesTo rdf:resource="&idmp-euctr;FendrixAsAuthorizedMedicinalProduct"/>
		<cmns-cxtdsg:isApplicableIn rdf:resource="&cmns-ge-euj;EuropeanUnion"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;FendrixPharmaceuticalProduct">
		<rdf:type rdf:resource="&idmp-mprd;PharmaceuticalProduct"/>
		<rdfs:label>Fendrix suspension For injection in pre-filled syringe PP</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;AluminumPhosphateAsActiveIngredient"/>
		<cmns-col:comprises rdf:resource="&idmp-euctr;HepatitisBSurfaceAntigenAsActiveIngredient"/>
		<cmns-col:comprises rdf:resource="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/EuropeanUnionClinicalTrialsRegister/MonophosphorylLipidA-1-3-O-desacyl-4&apos;AsActiveIngredient"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;GlaxoSmithKlineBiologicalsAsMarketingAuthorizationHolder">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorizationHolder"/>
		<rdfs:label>GlaxoSmithKline Biologicals as marketing authorization holder</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-euctr;GlaxoSmithKlineBiologicalsSA"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;GlaxoSmithKlineBiologicalsSA">
		<rdf:type rdf:resource="&cmns-org;LegalEntity"/>
		<rdfs:label>GlaxoSmithKline Biologicals s.a.</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;HepatitisBSurfaceAntigenAsActiveIngredient">
		<rdf:type rdf:resource="&idmp-sub;ActiveIngredient"/>
		<rdfs:label>hepatitis B surface antigen as an active ingredient</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://gsrs.ncats.nih.gov/api/v1/substances/e67c9314-1e17-4876-a745-47f27c2169e6"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;HeplisavAsInvestigationalMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;InvestigationalMedicinalProduct"/>
		<rdfs:label>HEPLISAV as investigational medicinal product</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/heplisav"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;HeplisavPharmaceuticalProduct">
		<rdf:type rdf:resource="&idmp-mprd;PharmaceuticalProduct"/>
		<rdfs:label>HEPLISAV suspension For injection PP</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;HepatitisBSurfaceAntigenAsActiveIngredient"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;MarketingAuthorizationNumber-CPMP-1493-01">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorizationNumber"/>
		<rdfs:label>marketing authorization number CPMP-1493-01</rdfs:label>
		<cmns-id:identifies rdf:resource="&idmp-euctr;FendrixMarketingAuthorizationInEuropeanUnion"/>
		<cmns-ra:isRegisteredBy rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-txt:hasTextValue>CPMP/1493/01</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;MarketingAuthorizationNumber-EMEA-H-C-000550">
		<rdf:type rdf:resource="&idmp-mprd;MarketingAuthorizationNumber"/>
		<rdfs:label>marketing authorization number EMEA-H-C-000550</rdfs:label>
		<cmns-id:identifies rdf:resource="&idmp-euctr;FendrixMarketingAuthorizationInEuropeanUnion"/>
		<cmns-ra:isRegisteredBy rdf:resource="&idmp-eurga;EuropeanMedicinesAgencyAsMedicinesRegulatoryAgency"/>
		<cmns-txt:hasTextValue>EMEA/H/C/000550</cmns-txt:hasTextValue>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://spec.pistoiaalliance.org/idmp/ontology/EXT/Examples/EuropeanUnionClinicalTrialsRegister/MonophosphorylLipidA-1-3-O-desacyl-4&apos;AsActiveIngredient">
		<rdf:type rdf:resource="&idmp-sub;ActiveIngredient"/>
		<rdfs:label>1-3-O-desacyl-4&apos; monophosphoryl lipid A as an active ingredient</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="https://gsrs.ncats.nih.gov/api/v1/substances/c9925b82-5d36-4e00-b54d-d3b7189625de"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;NorvascAsInvestigationalMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;InvestigationalMedicinalProduct"/>
		<rdfs:label>Norvasc as investigational medicinal product</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-amp;NorvascMedicinalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;NovartisPharmaServicesAG">
		<rdf:type rdf:resource="&cmns-org;LegalEntity"/>
		<rdfs:label>Novartis Pharma Services AG</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;NovartisPharmaServicesAGAuthorizedParty">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedParty"/>
		<rdfs:label>Novartis Pharma Services AG as authorized party</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-euctr;NovartisPharmaServicesAG"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;SheffieldTeachingHospitalsNHSFoundation">
		<rdf:type rdf:resource="&cmns-org;LegalEntity"/>
		<rdfs:label>Sheffield Teaching Hospitals NHS Foundation Trust</rdfs:label>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;SheffieldTeachingHospitalsNHSFoundationTrustAuthorizedParty">
		<rdf:type rdf:resource="&idmp-mprd;AuthorizedParty"/>
		<rdfs:label>Sheffield Teaching Hospitals NHS Foundation Trust as authorized party</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-euctr;SheffieldTeachingHospitalsNHSFoundation"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="&idmp-euctr;TerlipressinAcetateSUN0.12MgPerMlSolutionForInjectionAsInvestigationalMedicinalProduct">
		<rdf:type rdf:resource="&idmp-mprd;InvestigationalMedicinalProduct"/>
		<rdfs:label>Terlipressin Acetate SUN 0.12Mg Per Ml Solution For Injection as investigational medicinal product</rdfs:label>
		<cmns-cmp:isPlayedBy rdf:resource="&idmp-trlp;TerlipressinAcetateSUN0.12MgPerMlSolutionForInjection"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.clinicaltrialsregister.eu/ctr-search/trial/2004-002410-11/DE">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrial"/>
		<rdfs:label>A double-blind, randomized, multicenter 8 weeks study to evaluate the efficacy and safety of of valsartan / amlodipine combination based therapy versus amlodipine monotherapy based therapy in patients with stage II hypertension</rdfs:label>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;AliskirenAsInvestigationalMedicinalProduct"/>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;NorvascAsInvestigationalMedicinalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.clinicaltrialsregister.eu/ctr-search/trial/2010-022372-31/DE">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrial"/>
		<rdfs:label>Immunogenicity and Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End Stage Renal Disease Patients</rdfs:label>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;EngerixBAsInvestigationalMedicinalProduct"/>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;HeplisavAsInvestigationalMedicinalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000236-26/GB">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrial"/>
		<rdfs:label>An exploratory study to investigate the haemodynamic effects of serelaxin in patients with compensated cirrhosis and portal hypertension</rdfs:label>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;TerlipressinAcetateSUN0.12MgPerMlSolutionForInjectionAsInvestigationalMedicinalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-002112-16/GB">
		<rdf:type rdf:resource="&idmp-mprd;ClinicalTrial"/>
		<rdfs:label>Comparison of Fendrix and double-dose Engerix B in HIV non-responders</rdfs:label>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;EngerixBAsInvestigationalMedicinalProduct"/>
		<idmp-mprd:managesAdministrationOf rdf:resource="&idmp-euctr;FendrixAsInvestigationalMedicinalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/medicines/human/EPAR/fendrix">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>Fendrix suspension For injection in pre-filled syringe</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;FendrixPharmaceuticalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/medicines/human/referrals/engerix-b">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>Engerix B</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;EngerixBPharmaceuticalProduct"/>
	</owl:NamedIndividual>
	
	<owl:NamedIndividual rdf:about="https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/heplisav">
		<rdf:type rdf:resource="&idmp-mprd;MedicinalProduct"/>
		<rdfs:label>HEPLISAV suspension For injection</rdfs:label>
		<cmns-col:comprises rdf:resource="&idmp-euctr;HeplisavPharmaceuticalProduct"/>
	</owl:NamedIndividual>

</rdf:RDF>